Browse by Journal Title

2023

Assessment of pre-clinical liver models based on their ability to predict the liver-tropism of adeno-associated virus vectors.
Westhaus, A., Cabanes Creus, M., Dilworth, K.L., Zhu, E., Salas, D., Navarro, R.G., Amaya, A.K., Scott, A., Kwiatek, M., McCorkindale, A.L., Hayman, T.E., Frahm, A., Perocheau, D., Tran, B.M., Vincan, E., Wong, S.L., Waters, S.A., Riddiough, G.E., Perini, M.V., Wilson, L.O.W., Baruteau, J., Diecke, S., Gonzalez-Aseguinolaza, G., Santilli, G., Thrasher, A.J., Alexander, I.E. and Lisowski, L.
Human Gene Therapy 34 (7-8): 273-288. April 2023

2021

Gene therapy "Made in Germany": a historical perspective, analysis of the status quo, and recommendations for action by the German Society for Gene Therapy.
Büning, H., Fehse, B., Ivics, Z., Kochanek, S., Koehl, U., Kupatt, C., Mussolino, C., Nettelbeck, D.M., Schambach, A., Uckert, W., Wagner, E. and Cathomen, T.
Human Gene Therapy 32 (19-20): 987-996. 18 October 2021

Generation of Epstein-Barr virus antigen-specific T cell receptors recognizing immunodominant epitopes of LMP1, LMP2A, and EBNA3C for immunotherapy.
Dudaniec, K., Westendorf, K., Nössner, E. and Uckert, W.
Human Gene Therapy 32 (17-18): 919-935. 21 September 2021

2020

CD8-specific designed ankyrin repeat proteins improve selective gene delivery into human and primate T lymphocytes.
Frank, A.M., Weidner, T., Brynza, J., Uckert, W., Buchholz, C.J. and Hartmann, J.
Human Gene Therapy 31 (11-12): 679-691. June 2020

2018

Efficient non-viral T cell engineering by Sleeping Beauty minicircles diminishing DNA toxicity and miRNAs silencing the endogenous TCR.
Clauss, J., Obenaus, M., Miskey, C., Ivics, Z., Izsvák, Z., Uckert, W. and Bunse, M.
Human Gene Therapy 29 (5): 569-584. May 2018

2017

Unbiased identification of T cell receptors targeting immunodominant peptide-MHC complexes for T cell receptor immunotherapy.
Lorenz, F.K.M., Ellinger, C., Kieback, E., Wilde, S., Lietz, M., Schendel, D.J. and Uckert, W.
Human Gene Therapy 28 (12): 1158-1168. 1 December 2017

Wide awake and ready to move: 20 years of non-viral therapeutic genome engineering with the Sleeping Beauty transposon system.
Hodge, R., Narayanavari, S., Izsvák, Z. and Ivics, Z.
Human Gene Therapy 28 (10): 842-855. 1 October 2017

2011

Nonviral gene delivery with the Sleeping Beauty transposon system.
Ivics, Z. and Izsvak, Z.
Human Gene Therapy 22 (9): 1043-1051. September 2011

2010

Herpes simplex virus/Sleeping Beauty Vector-based embryonic gene transfer using the HSB5 mutant: loss of apparent transposition hyperactivity in vivo.
de Silva, S., Mastrangelo, M.A., Lotta, L.T., Burris, C.A., Izsvak, Z., Ivics, Z. and Bowers, W.J.
Human Gene Therapy 21 (11): 1603-1613. 19 November 2010

Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells caused serious adverse events.
Buening, H., Uckert, W., Cichutek, K., Hawkins, R.E. and Abken, H.
Human Gene Therapy 21 (9): 1039-1042. September 2010

Phase I trial of an allogeneic gene-modified tumor cell vaccine (RCC-26/CD80/IL-2) in patients with metastatic renal cell carcinoma.
Buchner, A., Pohla, H., Willimsky, G., Frankenberger, B., Frank, R., Baur-Melnyk, A., Siebels, M., Stief, C.G., Hofstetter, A., Kopp, J., Pezzutto, A., Blankenstein, T., Oberneder, R. and Schendel, D.J.
Human Gene Therapy 21 (3): 285-297. March 2010

2006

Uptake, biodistribution, and time course of naked plasmid DNA trafficking after intratumoral in vivo jet injection.
Walther, W., Minow, T., Martin, R., Fichtner, I., Schlag, P.M. and Stein, U.
Human Gene Therapy 17 (6): 611-624. 15 June 2006

2005

Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes.
Engels, B., Noessner, E., Frankenberger, B., Blankenstein, T., Schendel, D.J. and Uckert, W.
Human Gene Therapy 16 (7): 799-810. 1 July 2005

2003

Adenoviral natural born killer gene therapy for malignant glioma.
Naumann, U., Schmidt, F., Wick, W., Frank, B., Weit, S., Gillissen, B., Daniel, P. and Weller, M.
Human Gene Therapy 14 (13): 1235-1246. 1 September 2003

Retroviral vectors for high-level transgene expression in T lymphocytes.
Engels, B., Cam, H., Schueler, T., Indraccolo, S., Gladow, M., Baum, C., Blankenstein, T. and Uckert, W.
Human Gene Therapy 14 (12): 1155-1168. 10 August 2003

2002

Liposomal gene therapy with the herpes simplex thymidine kinase gene/ganciclovir system for the treatment of glioblastoma multiforme.
Voges, J., Weber, F., Reszka, R., Sturm, V., Jacobs, A., Heiss, W.D., Wiestler, O. and Kapp, J.F.
Human Gene Therapy 13 : 675-685. 1 January 2002

2000

A phase I study of intralesional administration of an adenovirus vector expressing the HSV-1 thymidine kinase gene (AdV.RSV-TK) in combination with escalating doses of ganciclovir in patients with cutaneous metastatic malignant melanoma.
Morris, J.C., Ramsey, W.J., Wildner, O., Muslow, H.A., Aguilar-Cordova, E. and Blaese, R.M.
Human Gene Therapy 11 : 487-503. 10 February 2000

Efficient gene transfer into primary human CD8+ T lymphocytes by MuLV-10A1 retrovirus pseudotype.
Uckert, W., Becker, C., Gladow, M., Klein, D., Kammertoens, T., Pedersen, L. and Blankenstein, T.
Human Gene Therapy 11 (7): 1005-1014. 1 January 2000

1999

Liposomal encapsulation of ganciclovir enhances the efficacy of herpes simplex virus type 1 thymidine kinase suicide gene therapy against hepatic tumors in rats.
Engelmann, C., Panis, Y., Bolard, J., Diquet, B., Fabre, M., Nagy, H., Soubrane, O., Houssin, D. and Klatzmann, D.
Human Gene Therapy 10 : 1545-1551. 10 June 1999

Efficient gene delivery into human dendritic cells by adenovirus polyethylenimine and mannose polyethylenimine transfection.
Diebold, S.S., Lehrmann, H., Kursa, M., Wagner, E., Cotten, M. and Zenke, M.
Human Gene Therapy 10 : 775-786. 20 March 1999

1998

Strong immunogenic potential of a B7 retroviral expression vector: Generation of HLA-B7-restricted CTL response against selectable marker genes.
Jung, D., Jaeger, E., Cayeux, S., Blankenstein, T., Hilmes, C., Karbach, J., Moebius, U., Knuth, A., Huber, C. and Seliger, B.
Human Gene Therapy 9 : 53-62. 1 January 1998

Double suicide gene (cytosine deaminase and herpes simplex virus thymidine kinase) but not single gene transfer allows reliable elimination of tumor cells in vivo.
Uckert, W., Kammertoens, T., Haack, K., Qin, Z., Gebert, J., Schendel, D.J. and Blankenstein, T.
Human Gene Therapy 9 : 855-865. 1 January 1998

RNA levels of human retrovirus receptors Pit1 and Pit2 do not correlate with infectibility by three retroviral vector pseudotypes.
Uckert, W., Willimsky, G., Pedersen, F.S., Blankenstein, T. and Pedersen, L.
Human Gene Therapy 9 : 2619-2627. 1 January 1998

Ex vivo breast cancer cell purging by adenovirus- mediated cytosine deaminase gene transfer and short-term incubation with 5-Fluorocytosine completely prevents tumor growth after transplantation.
Wolff, G., Koerner, I., Schumacher, A., Arnold, W., Doerken, B. and Mapara, M.Y.
Human Gene Therapy 9 : 2277-2284. 1 January 1998

1997

Role of alveolar macrophages in rapid elimination of adenovirus vectors administered to the epithelial surface of the respiratory tract.
Worgall, S., Leopold, P.L., Wolff, G., Ferris, B., Van Roijen, N. and Crystal, R.G.
Human Gene Therapy 8 (14): 1675-1684. 20 September 1997

Transient expression of SV 40 large T antigen by Cre/LoxP mediated site specific deletion in primary human tumor cells.
Li, L.P., Schlag, P.M. and Blankenstein, T.
Human Gene Therapy 8 : 1695-1700. 1 January 1997

Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration.
Worgall, S., Wolff, G., Falck-Pedersen, E. and Crystal, R.G.
Human Gene Therapy 8 : 37-44. 1 January 1997

1996

Gene transfer into hepatocytes and human liver tissue by baculovirus vectors.
Sandig, V., Hofmann, C., Steinert, S., Jennings, G., Schlag, P.M. and Strauss, M.
Human Gene Therapy 7 (16): 1937-1945. 20 October 1996

Coexpression of interleukin-4 and B7.1 in murine tumor cells leads to improved tumor rejection and vaccine effect compared to single gene transfectants and a classical adjuvant.
Cayeux, S., Beck, C., Doerken, B. and Blankenstein, T.
Human Gene Therapy 7 (4): 525-529. 1 January 1996

"Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype.
Mastrangeli, A., Harvey, B.G., Yao, J., Wolff, G., Kovesdi, I., Crystal, R.G. and Falck-Pedersen, E.
Human Gene Therapy 7 (1): 79-87. January 1996

1995

The thymidine kinase/ganciclovir-mediated "suicide" effect is highly variable in different tumor cells.
Beck, C., Cayeux, S., Lupton, S., Doerken, B. and Blankenstein, T.
Human Gene Therapy 6 (12): 1525-1530. 1 January 1995